Search results for "Factor XII"

showing 10 items of 33 documents

Isolation and Characterization of the Kininogen-binding Protein p33 from Endothelial Cells

1996

Abstract Kininogens, the precursor proteins of the vasoactive kinins, bind specifically, reversibly, and saturably to platelets, neutrophils, and endothelial cells. Two domains of the kininogens expose major cell binding sites: domain D3 that is shared by H- and L-kininogen and domain D5H that is exclusively present in H-kininogen. Previously we have mapped the kininogen cell binding sites to 27 residues of D3 (“LDC27”) and 20 residues of D5H (“HKH20”), respectively (Herwald, H., Hasan, A. A. K., Godovac-Zimmermann, J., Schmaier, A. H., and Muller-Esterl, W. (1995) J. Biol. Chem. 270, 14634-14642; Hasan, A. A. K., Cines, D. B., Herwald, H., Schmaier, A. H., and Muller-Esterl, W. (1995) J. B…

Kininogen bindingchemistry.chemical_classificationFactor XIIKininogenBinding proteinPrekallikreinPeptideCell BiologyBiologyBiochemistryMolecular biologyBiochemistryAffinity chromatographychemistryMolecular Biologycirculatory and respiratory physiologyBinding domainJournal of Biological Chemistry
researchProduct

Missense mutations of coagulation factor XII in hereditary angioedema with normal complement C1 inhibitor

2007

biologybusiness.industryImmunologyCoagulation Factor XIImedicine.diseaseComplement (complexity)C1-inhibitorHereditary angioedemaImmunologymedicinebiology.proteinMissense mutationbusinessMolecular BiologyMolecular Immunology
researchProduct

Hereditary Angioedema with Normal C1 Inhibitor Activity Including Hereditary Angioedema with Coagulation Factor XII Gene Mutations

2006

Recurrent angioedema of the skin is a commonly diagnosed clinical symptom that can be found in various clinical entities [1,2]. Some types of angioedema of the skin are associated with episodes of upper airway obstruction that may be life threatening. Death by asphyxiation from laryngeal edema is well known in hereditary angioedema (HAE) due to C1 inhibitor deficiency [3,4] and in recurrent angioedema induced by angiotensinconverting enzyme (ACE) inhibitors [5–9]. Therefore, it is important to determine the exact type of angioedema in each patient. In many patients angioedema is associated with urticaria. If relapsing urticaria occurs simultaneously or alternately with angioedema, both cond…

MaleAllergymedicine.medical_specialtyImmunologyGene mutationLaryngeal EdemaC1-inhibitorimmune system diseasesHumansImmunology and AllergyMedicinecardiovascular diseasesAngioedemaskin and connective tissue diseasesAspirinAngioedemabiologybusiness.industryfood and beveragesmedicine.diseaseDermatologyPedigreeFactor XIIMutationImmunologyHereditary angioedemaSerum sicknessbiology.proteinFemalemedicine.symptombusinessComplement C1 Inhibitor Proteinmedicine.drugImmunology and Allergy Clinics of North America
researchProduct

Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels

2016

Background Hereditary angioedema with normal C1 inhibitor levels (HAE-N) is associated with a Factor XII mutation in 30% of subjects; however, the role of this mutation in the pathogenesis of angioedema is unclear. Objective We sought evidence of abnormalities in the pathways of bradykinin formation and bradykinin degradation in the plasma of patients with HAE-N both with and without the mutation. Methods Bradykinin was added to plasma, and its rate of degradation was measured by using ELISA. Plasma autoactivation was assessed by using a chromogenic assay of kallikrein formation. Plasminogen activator inhibitors (PAIs) 1 and 2 were also measured by means of ELISA. Results PAI-1 levels varie…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentImmunologyBradykinin030204 cardiovascular system & hematologyArticleC1-inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineFibrinolysismedicineImmunology and AllergyFactor XIIAngioedemabiologybusiness.industryKallikreinmedicine.disease030104 developmental biologyEndocrinologychemistryPlasminogen activator inhibitor-1Hereditary angioedemabiology.proteinmedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct

Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).

2016

Hereditary angioedema with normal C1 esterase inhibitor and mutations in the F12 gene (HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. It occurs nearly exclusively in women. We report our experience treating HAE-FXII with discontinuation of potential trigger factors and drug therapies. The study included 72 patients with HAE-FXII. Potential triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors. Drug treatment comprised plasma-derived C1 inhibitor (pdC1-INH) for acute swelling attacks and progestins, tranexamic acid, and danaz…

0301 basic medicineAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyAngiotensin-Converting Enzyme InhibitorsGastroenterologyChemopreventionC1-inhibitorHereditary Angioedema Type III03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicinemedicineImmunology and AllergyHumansHereditary Angioedema Type IIIChildAgedDanazolbiologybusiness.industryEstrogensMiddle Agedmedicine.diseaseSurgeryDiscontinuation030104 developmental biologyTreatment Outcome030228 respiratory systemQuinaprilHereditary angioedemaFactor XIIMutationbiology.proteinDisease ProgressionFemalebusinessComplement C1 Inhibitor ProteinTranexamic acidBiomarkersmedicine.drugAllergy
researchProduct

Hereditary angioedema with normal C1-INH withversuswithout specificF12gene mutations

2015

Background Hereditary angioedema with normal C1-INH may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or mutations in genes that are still unknown (HAE-unknown). To assess the differences in transmission and inheritance, clinical features, and laboratory parameters between patients with HAE-FXII and HAE-unknown. Methods Sixty-nine patients with HAE-FXII from 23 unrelated families and 196 patients with HAE-unknown from 65 unrelated families were studied. Results Both HAE-FXII and HAE-unknown are inherited as autosomal-dominant traits with incomplete penetrance. The male to female ratio was 1 : 68 in HAE-FXII and 1 : 6.3 in HAE-unknown. The maternal to pa…

AdultMalemedicine.medical_specialtyDatabases FactualOffspringImmunologyGene mutationSeverity of Illness IndexCohort StudiesYoung Adultchemistry.chemical_compoundAge DistributionInternal medicineHumansImmunology and AllergyMedicineHereditary Angioedema Type IIIAge of OnsetSex DistributionRetrospective Studiesmedicine.diagnostic_testAngioedemabusiness.industryIncidenceAngioedemas HereditaryMiddle AgedPrognosismedicine.diseasePenetranceRecombinant ProteinsPedigreePhenotypeEndocrinologychemistryPlasminogen activator inhibitor-1Factor XIIMutationHereditary angioedemaFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinPartial thromboplastin timeAllergy
researchProduct

Severe plasma prekallikrein deficiency : clinical characteristics, novel KLKB1 mutations, and estimated prevalence

2020

BACKGROUND Severe plasma prekallikrein (PK) deficiency is an autosomal-recessive defect characterized by isolated activated partial thromboplastin time prolongation. To date, no comprehensive methodologically firm analysis has investigated the diagnostic, clinical, and genetic characteristics of PK deficiency, and its prevalence remains unknown. PATIENTS/METHODS We described new families with PK deficiency, retrieved clinical and laboratory information of cases systematically searched in the (gray) literature, and collected blood of these cases for complementary analyses. The Genome Aggregation Database (gnomAD) and the population-based Gutenberg Health Study served to study the prevalence …

medicine.medical_specialty2720 HematologyPopulation610 Medizin610 Medicine & healthReference range030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePlasma PrekallikreinInternal medicine610 Medical sciencesPrevalenceHumansMedicineeducation610 Medicine & healthFactor XIIeducation.field_of_studymedicine.diagnostic_testbusiness.industry10031 Clinic for AngiologyPrekallikreinPrekallikreinHematologyBlood Coagulation Disordersmedicine.diseaseThrombosisMutation10032 Clinic for Oncology and HematologyCohortbusinessPartial thromboplastin time
researchProduct

Crosstalk of the plasma contact system with bacteria.

2012

Activation of the plasma contact system triggers several cascade systems such as the kallikrein-kinin system, the intrinsic pathway of coagulation, the classical complement cascade and the fibrinolytic system. Recent studies have shown a critical role of the contact system for arterial and venous thrombus formation and thromboembolic disease. In contrast, the function of the contact system for host-defense reactions and its physiological functions have remained enigmatic. Experimental animal studies and clinical data have linked the contact system to bacterial infections with implications for sepsis disease. The present review summarizes the role of the contact system and its activation for…

Kallikrein-Kinin SystemVascular permeabilityBiologySepsisCapillary PermeabilitySepsismedicineAnimalsHumansComplement Pathway ClassicalThrombusBlood CoagulationFactor XIIFibrinInnate immune systemBacteriaFibrinolysisHematologyBacterial Infectionsmedicine.diseaseImmunity InnateComplement systemCrosstalk (biology)ImmunologySignal transductionSignal TransductionThrombosis research
researchProduct

A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor.

2011

In hereditary angioedema with normal C1-inhibitor two different missense mutations of codon p.Thr328* in the coagulation factor 12 gene have been reported in some families. In this study a novel factor 12 gene mutation, the deletion of 72 base pairs (bp) (c.971_1018+24del72*), was identified in a family of Turkish origin, in two sisters with recurrent skin swellings and abdominal pain attacks and in their symptom-free father. This deletion caused a loss of 48 bp of exon 9 (coding amino acids 324* to 340*) in addition to 24 bp of intron 9, including the authentic donor splice site of exon 9. The large deletion of 72 bp was located in the same F12 gene region as the missense mutations p.Thr32…

AdultMaleFactor XII DeficiencyTurkeyImmunologyDNA Mutational AnalysisMutation MissenseGene mutationmedicine.disease_causeC1-inhibitorExonImmunology and AllergyMedicineMissense mutationHumansHereditary Angioedema Type IIISequence DeletionGeneticsMutationAngioedemabiologybusiness.industryAngioedemas HereditaryExonsmedicine.diseaseMolecular biologyIntronsPedigreeHereditary angioedemaFactor XIIMutationbiology.proteinFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinClinical immunology (Orlando, Fla.)
researchProduct

Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment acco…

1984

The thrombocyte count, the factor XIII (F XIII) activity, the concentration of fibrinogen (F I), prothrombin (F II), fibronectin (CIG), albumin and the proteinase inhibitors antithrombin III (AT III), alpha 2-macroglobulin (A2M), alpha 1-antitrypsin (A1A) and Cl-esterase inactivator (Cl-INA) were determined in ten children with acute lymphoblastic leukaemia (ALL). Changes due to the disease and to therapy were observed. Before the start of treatment the patients had thrombocytopenia secondary to the disease, and the proteinase inhibitors--especially Cl-INA and A1A--were raised. During the induction phase the thrombocyte count rose but there was also a marked increase in the concentration of…

Malemedicine.medical_specialtyAdolescentAntithrombin IIIAlpha (ethology)Complement C1 Inactivator ProteinsFibrinogenMaintenance therapyInternal medicineDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtease Inhibitorsalpha-MacroglobulinsChildGenetics (clinical)Factor XIIIbusiness.industryAntithrombinAlbuminFibrinogenGeneral MedicineFactor XIIIMolecular medicineBlood Coagulation FactorsFibronectinsLeukemia LymphoidEndocrinologyCoagulationChild Preschoolalpha 1-AntitrypsinImmunologyMolecular MedicineFemaleProthrombinbusinessmedicine.drugKlinische Wochenschrift
researchProduct